pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 1·1 min read
save

Premium subscribers invited to exclusive post-hoc Q1 earnings recap live event

May 1, 2026·read at Endpoints ↗Neutral

A live, post‑hoc session will be held for premium subscribers that reviews first‑quarter earnings across the pharmaceutical sector, with a particular focus on the deal activity reported in the calls.

The event, organized by Endpoints News, will break down the news and trends emerging from big‑pharma Q1 earnings calls, offering analysis and context for investors and industry professionals.

Access to the session is limited to premium members only. Non‑subscribers are encouraged to upgrade to gain unlimited access to this and other exclusive content.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Save the date: Premium subscriber-exclusive Post-Hoc Live”

read at Endpoints ↗
61 words · retrieved May 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Big Pharma

related stories

  • Jul 21Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsBioSpace
  • Jul 20Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsBioSpace
  • Jul 20BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’Fierce Biotech
  • Jul 18‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsFierce Biotech
  • Jul 17Compounders maintain a firm grip on the GLP-1 marketBioPharma Dive